Household & Personal Products. Scored on the same transparent model behind the daily rankings.
★
CLX
The Clorox Company · Household & Personal Products
53.9Score
$83.80Oct 9 close$10.1B
1Y Target$99.59Analyst consensus · 17 analysts
5Y Target$145.81Compound horizon
10Y Target$216.30Long-dated conviction
FCF$405mTTM · 06/26C
FCF $405m — modest; watch for margin expansion · Trailing twelve months to 06/26 (operating cash flow − capex).
Rev-5.4%FY YoYD
Revenue -5.4% — meaningful contraction · Computed from the last two annual revenue figures (FY YoY).
D/E*——
No debt-to-equity ratio to show (see the note below the grades)
P/E17.4xB
P/E 17.4 — near the Consumer Defensive median (≈60th pctile)
PEG1.04B+
PEG 1.04 — near fair value (1.0 is the usual benchmark)
* D/E omitted — equity is negative or tiny next to debt
Targets: 1-year is analyst consensus where covered, 5- and 10-year are model estimates; the DCF is a cross-check, not a target. Methodology
Quality-growth score · 53.9
Quality79.4
Growth31.1
Value63.5
Entry · Margin of safety
52-week rangeNear 52-week low
35% off the 12-month high
vs DCF fair value19% aboveest. fair value ~$70
What the price assumes: free cash flow growing about 6% next year, slowing to 4% a year by year ten — vs a starting rate of ~1% our model takes as the middle of three readings — analyst estimates, last year's revenue growth, and the company's own multi-year record.
Model-generatedFrom reported fundamentals, checked against the figures above · Editorial standards
Why now
Household & Personal Products · market cap $10.1b. Down 35% from 52-week high of $128.90 — deep drawdown territory. Revenue -5% — in contraction; any catalyst that reverses this triggers re-rating. 17 sell-side analysts rate this a Hold with a mean 1-yr target of $99.59 (implying +19% upside).
Moat
Moat signals from the quantitative card are modest — profitability and capital efficiency are middle-of-pack. The thesis here depends on softer factors (switching costs, brand, distribution, regulatory protection) not captured by the quality-growth screen.
Risk
Revenue contracting -5% — the operational turn is not yet visible in the top line. Down 35% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Dividend payout 103% of earnings on a 6.0% yield — distribution coverage is thin; one earnings stumble could force a dividend cut.
Horizon
1-3 yr $99.59 (17-analyst consensus) — fundamentals + valuation re-rating. 5 yr $145.81 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $216.30 if current growth sustains into durable earnings power.
CLX vs the Top Picks average
Pillar
CLX
Book avg
Diff
Quality
79
83
-4
Growth
31
89
-58
Value
64
76
-12
Average of today's Top 30 (mean score 82.6); size and sector limits also decide the book.
Score history · CLX
Trend
+7.3 over 81 daily scores
From 46.6 (Jun 22) → 53.9 (now)
One point per daily run; read From → To for the actual range.
CLX at a glance
Same audited fundamentals as the score, unless a card says otherwise.
Analyst estimate revisions
30-day change
-1.3%
90-day change
+1.4%
Forward EPS estimate
$6.21
Over the last 90 days, what analysts expect CLX to earn is drifting higher (+1.4%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
Estimates move both ways and are not part of the Bull Rankings score. Biggest movers →
Position sizing · CLX
$
%
%
Shares to buy
23
Position size
$1,927
3.9% of portfolio
Stop price
$62.85
25% below $83.80
$ at risk if stopped
$481.85
budget $500.00 · 1% of portfolio
Math only: excludes commissions, slippage and gap risk. Inputs stay in your browser.
The Clorox Company (CLX): score, valuation & FAQ
The Clorox Company (CLX) is a Household & Personal Products company that scores 53.9 out of 100 on the Bull Rankings quality-growth model — a middling reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are PEG (B+), while Rev (D) rate weaker. On valuation, CLX sits about 19% above our discounted-cash-flow fair value — the current price implies free cash flow growing about 6% next year, slowing to 4% a year by year ten.
Is CLX a good stock to buy?
Bull Rankings scores CLX 53.9 out of 100 on its quality-growth model, which is a middling reading. That is driven by PEG (B+). A score is a quantitative screen of The Clorox Company's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does CLX score 53.9 on Bull Rankings?
The score leans on quality at 79.4 out of 100, with growth the weakest pillar at 31.1 — the three combine geometrically, so a weak one cannot be papered over by a strong one. CLX earns its highest marks on PEG (B+), and is held back by Rev (D). Each signal is graded against sector-aware thresholds rather than one absolute bar, so CLX is measured against Household & Personal Products peers, not against the market as a whole.
Is CLX overvalued or undervalued?
Based on $83.80, CLX sits about 19% above our discounted-cash-flow fair value — the current price implies free cash flow growing about 6% next year, slowing to 4% a year by year ten. It trades at a 17.4x P/E (graded B). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in CLX?
Revenue contracting -5% — the operational turn is not yet visible in the top line. Down 35% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Dividend payout 103% of earnings on a 6.0% yield — distribution coverage is thin; one earnings stumble could force a dividend cut.